Fosgonimeton sodium clinical trials
Also written ATH-1017.
A product of Fosgonimeton; its studies count on that page too.
How each study uses fosgonimeton sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Athira Pharma (5)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Fosgonimeton
Studies
Open first, then newest update. How each study uses fosgonimeton sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseCompletedPhase 2/3Athira PharmaNCT04488419Written as ATH-1017
- Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2/3Athira PharmaNCT04886063Written as ATH-1017
- ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)TerminatedPhase 2Athira PharmaNCT04831281Written as ATH-1017
- A Study of ATH-1017 in Mild to Moderate Alzheimer's DiseaseCompletedPhase 2Athira PharmaNCT04491006Written as ATH-1017
- Safety, Tolerability, and Pharmacokinetics Study of NDX-1017CompletedPhase 1Athira PharmaNCT03298672Written as NDX-1017
Codes
What other systems call fosgonimeton sodium · ClinicalTrials.gg INT018279
- UNII (FDA) VX9KPJ1576FOSGONIMETON SODIUMOne source FDA
- NCI Thesaurus C188769Fosgonimeton SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VX9KPJ1576 | FOSGONIMETON SODIUM | One source FDA |
| NCI Thesaurus | C188769 | Fosgonimeton Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.